A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.

@article{Scoggins2010ANC,
  title={A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program.},
  author={J. Scoggins and S. Ramsey},
  journal={Journal of the National Cancer Institute},
  year={2010},
  volume={102 17},
  pages={
          1371
        }
}
  • J. Scoggins, S. Ramsey
  • Published 2010
  • Medicine
  • Journal of the National Cancer Institute
  • A recent Institute of Medicine (IOM) report (1) cited several deficiencies in the Clinical Trials Cooperative Group Program of the National Cancer Institute (NCI), including an inefficient and cumbersome oversight structure and a 20% reduction in funding since 2002. The authors concluded that these and other problems have resulted in start-up times for phase III Cooperative Group trials that range from 1.25 to almost 7 years and a clinical trial completion rate of only 50%. They also noted that… CONTINUE READING
    207 Citations

    Topics from this paper.

    Adult cancer clinical trials that fail to complete: an epidemic?
    • 50
    • PDF
    Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer.
    • 7
    • PDF
    Wither the cooperative groups?
    • R. Schilsky
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2014
    • 7
    Nurse scientists in cancer cooperative groups.
    • 3

    References

    SHOWING 1-10 OF 12 REFERENCES
    Translational Research Working Group Developmental Pathway for Immune Response Modifiers
    • 37
    • PDF
    CTWG evaluation plan: Results of baseline feasibility analysis
    • Presented at the National Cancer Advisory Board Meeting, February 2008, Bethesda, MD.
    • 2008
    Compressing the timeline for cancer clinical trial activation
    • Operational Efficiency Working Group final report. Presented at the Clinical and Translational Research Advisory Committee, March 2010, Bethesda, MD.
    • 2010
    Durling Professor of Medicine (2006), and is a Mayo Clinic
    • Distinguished Investigator
    • 2006
    President’s Cancer Panel 200 –200 Annual Report: Translating research into cancer care: Delivering on the promise
    • Bethesda, MD: National Cancer Institute.
    • 2005